| Product Unit Size | Cost | Quantity | Stock |
|---|
Baloxavir, and its prodrug baloxavir marboxil, is a cap-dependent endonuclease inhibitor, leading to inhibition of RNA transcription and replication. Baloxavir shows potent activity against two influenza A strains with noted synergistic effects when used in combination with oseltamivir. It has also been investigated for its potential to treat COVID-19 but no proven benefit has been observed.
| Cas No. | 1985605-59-1 |
|---|---|
| Purity | ≥ 99% |
| Formula | C24H19F2N3O4S |
| Formula Wt. | 483.5 |
| IUPAC Name | (3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-11-hydroxy-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione |
| Synonym | Baloxavir acid, 4G86Y4JT3F |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Checkmahomed L, Padey B, Pizzorno A, et al. In vitro combinations of baloxavir acid and other inhibitors against seasonal influenza A viruses. Viruses. 2020 Oct 8;12(10):1139. PMID: 33049959.
Lou Y, Yao H, Hu X, et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci. 2020 Oct 25;105631. PMID: 33115675.
Janabi A. Effective anit-SARS-CoV-2 RNA dependent RNA polymerase drugs based on docking methods: the case of milbemycin, ivermectin, and baloxavir marboxil. Avicenna J Med Biotechnol. 2020 Oct-Dec;12(4):246-250. PMID: 33014317.
Saito R, Osada H, Wagatsuma K, et al. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza A viruses with polymerase acidic subunit substitutions. Antiviral Res. 2020 Nov;183:104951. PMID: 32987032.